Compare PMM & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PMM | LUNG |
|---|---|---|
| Founded | 1989 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Industrial Specialties |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 269.4M | 57.9M |
| IPO Year | N/A | 2020 |
| Metric | PMM | LUNG |
|---|---|---|
| Price | $6.36 | $1.28 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $5.38 |
| AVG Volume (30 Days) | 86.8K | ★ 347.0K |
| Earning Date | 01-01-0001 | 04-29-2026 |
| Dividend Yield | ★ 4.68% | N/A |
| EPS Growth | N/A | ★ 7.64 |
| EPS | ★ 0.23 | N/A |
| Revenue | N/A | ★ $90,497,000.00 |
| Revenue This Year | N/A | $2.48 |
| Revenue Next Year | N/A | $18.46 |
| P/E Ratio | $27.65 | ★ N/A |
| Revenue Growth | N/A | ★ 8.01 |
| 52 Week Low | $5.77 | $1.13 |
| 52 Week High | $6.52 | $3.88 |
| Indicator | PMM | LUNG |
|---|---|---|
| Relative Strength Index (RSI) | 66.57 | 39.38 |
| Support Level | $6.06 | $1.19 |
| Resistance Level | $6.40 | $1.67 |
| Average True Range (ATR) | 0.05 | 0.12 |
| MACD | 0.01 | -0.04 |
| Stochastic Oscillator | 100.00 | 12.12 |
Putnam Managed Municipal Income Trust is a closed-end management investment company. Its investment objective is to seek a high level of current income exempt from federal income tax by investing in a diversified portfolio of tax-exempt municipal securities. The Fund invests in various sectors such as healthcare, retirement community, private higher education, housing-backed, essential service utilities, and state-backed bonds.
Pulmonx Corp is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System), and the LungTraX Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. The majority of the company's revenue is generated from the provision of cloud hosting and management services. The company geographically, operates in the USA, the EMEA, the Asia Pacific, and other international regions, the majority of revenue from USA.